Key players are focused on development of novel products to sustain their position in the highly consolidated market
Key players operating in the global diabetes injection pens market include Novo Nordisk A/S, AstraZeneca Plc, Biocon Ltd, Eli Lilly and Company, Becton, Dickinson and Company, and Jiangsu Delfu Co. Major players are consistently focused towards innovation and development in the existing technology to maintain their significance and establish their presence in the global diabetes injection pens market. For instance, Novo Nordisk in 2014 introduced a new insulin injection pen device NovoPen Echo that was the first-ever injection pen to deliver half a unit of insulin, with a memory function that records last dose and the time passed since the last injection.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients